NicOx Gives Full Details Of Naproxcinod Phase 3 Plan In Osteoarthritis And An Update On Other R&D Programs

... NicOx S.A. (Eurolist: NICOX) is today announcing the full details of the phase 3clinical program it has designed to gain regulatory approval fornaproxcinod (HCT 3012) for treating the signs and symptoms ofosteoarthritis (OA) in the United States (US) and Europe. The plan consistsof three phase 3 efficacy trials, the first of which is currently ongoingin knee OA in the U.S. [click link for full article] ...